top of page

DEVELOPMENT

Our programme

This page states where the programme stands. It makes no claim about what our candidate does.

The candidate

Our lead candidate, VRX-001, is a cannabinoid new chemical entity

VRX-001 is an investigational medicinal product. It is not authorised in any territory and is not available for supply. Varex Bio does not supply it, or any product containing it, to any person.

Where we are

Stage

Pre-clinical

Indication under study

22q11.2 deletion syndrome

Marketing authorisation

None, in any territory

Patents

Method-of-use applications filed

Registered studies

None yet. When a study is registered it will be listed here with a link to the public trial registry

How we work

Varex Bio's freedom-to-operate position derives exclusively from published patent documents and public prosecution history. No confidential or proprietary information of any former employer has been used, and none is required.

Development is planned across the United Kingdom, Australia and the United States.

What we do not say here

Varex Bio makes no claim about the safety or the efficacy of its candidate. Those are the questions the research programme exists to answer, and any answers will be reported through regulatory submission and peer-reviewed publication rather than through this website.

Varex Bioscience Limited (Varex Bio). Registered in England and Wales, company number 17220992. Registered office: 89 Gawsworth Road, Macclesfield, England, SK11 8UQ.

​​

​VRX-001 is an investigational medicinal product. It is not authorised in any territory and is not available for supply. Varex Bio does not supply it, or any product containing it, to any person.

​​​

Nothing on this website is an offer of securities, an invitation to invest, or investment, legal, tax or medical advice. This website is directed at readers in the United Kingdom and is not directed at US persons. Statements about future plans are subject to change.

​

Varex Bio is not a member of the Association of the British Pharmaceutical Industry and has not accepted the jurisdiction of the Prescription Medicines Code of Practice Authority. This website has been prepared having regard to the ABPI Code of Practice and the MHRA Blue Guide.

bottom of page